Multidrug-resistant Mycobacterium tuberculosis, Bangui, Central African Republic. 2006

Laurent X Nouvel, and Eric Kassa-Kelembho, and Tiago Dos Vultos, and Germain Zandanga, and Jean Rauzier, and Carmen Lafoz, and Carlos Martin, and Jesus Blazquez, and Antoine Talarmin, and Brigitte Gicquel
Institut Pasteur, Paris, France.

We investigated multidrug-resistant (MDR) Mycobacterium tuberculosis strains in Bangui, Central African Republic. We found 39.6% with the same spoligotype and synonymous single nucleotide polymorphism in the mutT1 gene. However, strains had different rpoB mutations responsible for rifampin resistance. MDR strains in Bangui may emerge preferentially from a single, MDR-prone family.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D009841 Oligonucleotides Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed) Oligonucleotide
D002488 Central African Republic A republic in central Africa south of CHAD and SUDAN, north of DEMOCRATIC REPUBLIC OF THE CONGO, and east of CAMEROON. The capital is Bangui. Ubangi-Shari
D004260 DNA Repair The removal of DNA LESIONS and/or restoration of intact DNA strands without BASE PAIR MISMATCHES, intrastrand or interstrand crosslinks, or discontinuities in the DNA sugar-phosphate backbones. DNA Damage Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D001426 Bacterial Proteins Proteins found in any species of bacterium. Bacterial Gene Products,Bacterial Gene Proteins,Gene Products, Bacterial,Bacterial Gene Product,Bacterial Gene Protein,Bacterial Protein,Gene Product, Bacterial,Gene Protein, Bacterial,Gene Proteins, Bacterial,Protein, Bacterial,Proteins, Bacterial
D012321 DNA-Directed RNA Polymerases Enzymes that catalyze DNA template-directed extension of the 3'-end of an RNA strand one nucleotide at a time. They can initiate a chain de novo. In eukaryotes, three forms of the enzyme have been distinguished on the basis of sensitivity to alpha-amanitin, and the type of RNA synthesized. (From Enzyme Nomenclature, 1992). DNA-Dependent RNA Polymerases,RNA Polymerases,Transcriptases,DNA-Directed RNA Polymerase,RNA Polymerase,Transcriptase,DNA Dependent RNA Polymerases,DNA Directed RNA Polymerase,DNA Directed RNA Polymerases,Polymerase, DNA-Directed RNA,Polymerase, RNA,Polymerases, DNA-Dependent RNA,Polymerases, DNA-Directed RNA,Polymerases, RNA,RNA Polymerase, DNA-Directed,RNA Polymerases, DNA-Dependent,RNA Polymerases, DNA-Directed
D018088 Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS. Tuberculosis, Drug-Resistant,Tuberculosis, MDR,Tuberculosis, Multi-Drug Resistant,Drug-Resistant Tuberculosis,MDR Tuberculosis,Multi-Drug Resistant Tuberculosis,Multidrug-Resistant Tuberculosis,Tuberculosis, Drug Resistant,Tuberculosis, Multi Drug Resistant,Tuberculosis, Multidrug Resistant

Related Publications

Laurent X Nouvel, and Eric Kassa-Kelembho, and Tiago Dos Vultos, and Germain Zandanga, and Jean Rauzier, and Carmen Lafoz, and Carlos Martin, and Jesus Blazquez, and Antoine Talarmin, and Brigitte Gicquel
February 1995, AIDS (London, England),
Laurent X Nouvel, and Eric Kassa-Kelembho, and Tiago Dos Vultos, and Germain Zandanga, and Jean Rauzier, and Carmen Lafoz, and Carlos Martin, and Jesus Blazquez, and Antoine Talarmin, and Brigitte Gicquel
May 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Laurent X Nouvel, and Eric Kassa-Kelembho, and Tiago Dos Vultos, and Germain Zandanga, and Jean Rauzier, and Carmen Lafoz, and Carlos Martin, and Jesus Blazquez, and Antoine Talarmin, and Brigitte Gicquel
June 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Laurent X Nouvel, and Eric Kassa-Kelembho, and Tiago Dos Vultos, and Germain Zandanga, and Jean Rauzier, and Carmen Lafoz, and Carlos Martin, and Jesus Blazquez, and Antoine Talarmin, and Brigitte Gicquel
August 2005, The American journal of tropical medicine and hygiene,
Laurent X Nouvel, and Eric Kassa-Kelembho, and Tiago Dos Vultos, and Germain Zandanga, and Jean Rauzier, and Carmen Lafoz, and Carlos Martin, and Jesus Blazquez, and Antoine Talarmin, and Brigitte Gicquel
November 1997, Lancet (London, England),
Laurent X Nouvel, and Eric Kassa-Kelembho, and Tiago Dos Vultos, and Germain Zandanga, and Jean Rauzier, and Carmen Lafoz, and Carlos Martin, and Jesus Blazquez, and Antoine Talarmin, and Brigitte Gicquel
July 2014, Emerging infectious diseases,
Laurent X Nouvel, and Eric Kassa-Kelembho, and Tiago Dos Vultos, and Germain Zandanga, and Jean Rauzier, and Carmen Lafoz, and Carlos Martin, and Jesus Blazquez, and Antoine Talarmin, and Brigitte Gicquel
January 2006, Sante (Montrouge, France),
Laurent X Nouvel, and Eric Kassa-Kelembho, and Tiago Dos Vultos, and Germain Zandanga, and Jean Rauzier, and Carmen Lafoz, and Carlos Martin, and Jesus Blazquez, and Antoine Talarmin, and Brigitte Gicquel
January 2002, Medecine tropicale : revue du Corps de sante colonial,
Laurent X Nouvel, and Eric Kassa-Kelembho, and Tiago Dos Vultos, and Germain Zandanga, and Jean Rauzier, and Carmen Lafoz, and Carlos Martin, and Jesus Blazquez, and Antoine Talarmin, and Brigitte Gicquel
August 2005, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
Laurent X Nouvel, and Eric Kassa-Kelembho, and Tiago Dos Vultos, and Germain Zandanga, and Jean Rauzier, and Carmen Lafoz, and Carlos Martin, and Jesus Blazquez, and Antoine Talarmin, and Brigitte Gicquel
January 2003, Sante (Montrouge, France),
Copied contents to your clipboard!